Importantly, melatonin and metformin demonstrated synergistic activities to ameliorate obesity, insulin sensitivity, circadian activity, and suppression of islet cell failure in CDO rats, and so slowing the onset of metabolic dysfunction. The gene discussed is INS; the disease is obesity due to melanocortin 4 receptor deficiency.